BioSpace News Archive

Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.

Context Therapeutics Inc. today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced that its strategic partner, Kaken Pharmaceutical Co. Ltd, launched NexoBrid® in Japan for the treatment of deep partial thickness and full thickness burns in adults and pediatric patients.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development.

Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following events in August.

Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its second quarter 2023 financial results and provide a corporate update.

Xeris Biopharma Holdings, Inc. today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, August 8, 2023.

Etiometry, the leader in clinical decision-support software, announced its IVCO2 Index™ was cleared by the Food and Drug Administration for use with neonatal ICU patients under 2kg, who are especially vulnerable to the effects of hypercapnia.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced $20 million in Series A extension funding committed by Apple Tree Partners (ATP).

Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced its participation in the following investor conference.